Navigation Links
Anthracyclines improve survival in HER2-positive breast cancer patients
Date:12/25/2007

Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online December 25 in the Journal of the National Cancer Institute.

Randomized clinical trials have demonstrated that treating early breast cancer with anthracycline-based chemotherapy improves disease-free and overall survival rates more than non-anthracycline-based regimens. However, the studies have demonstrated that anthracyclines may slightly increase the risk of heart damage and leukemia. Given these side effects, the greatest benefit of these regimens may be in women with breast tumors that overexpress HER2a gene that is often amplified in tumors that respond to anthracyclines.

Alessandra Gennari, M.D., Ph.D., of the National Cancer Research Institute in Genoa, Italy, and colleagues compiled data from eight randomized controlled trials that compared anthracyclines and non-anthracyclines, and also reported HER2 status. Almost 30 percent of the patients tumors overexpressed HER2.

Overall and among patients with HER2-positive tumors, anthracycline-based chemotherapy produced a greater reduction in the risk of relapse or death than non-anthracycline-based regimens. However, among patients with HER2-negative tumors, there was no difference in survival between the chemotherapy regimens.

The absenceof any effect of anthracyclines observed in patients with HER2-negative disease suggests that this group of patients could be spared unnecessary toxic effects related to the use of this class of agents and raises questions as to the appropriateness of control arms in randomized clinical trials in which anthracycline-based regimens are used in unselected patient populations, the authors write.

In an accompanying editorial, Soonmyung Paik, M.D., of the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh and colleagues point out that HER2 status alone may not be enough to determine who should receive anthracyclines, given the molecular differences among different subtypes of breast cancer.

Optimization of adjuvant chemotherapy for patients diagnosed with breast cancer will depend on defining the baseline prognosis and chemosensitivity of each subclass of breast cancer beyond those crudely defined by HER2 status alone, the editorialists write.


'/>"/>

Contact: Andrea Widener
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Vision restoration therapy shown to improve brain activity in brain injured patients
2. Broad-based group of physicians calls for improvement in stroke treatment
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. Pill box organizers increase HIV patients adherence and improve viral suppression
5. Treating depression may improve recovery of heart rate variability following coronary syndromes
6. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
7. AWWA, National Association of Water and Sanitation of Mexico, Agree to Share Expertise and Resources for Improved Water Supply
8. Exercise and yoga improves quality of life in women with early-stage breast cancer
9. QI projects may -- or may not -- improve patient safety and outcomes
10. National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Childrens Fitness
11. MedQuist Re-launches New, Improved Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 2016 , ... The U.S. Food and Drug Administration today ... submit their products through an arduous federal approval process. The rules, which treat ... market since February 15, 2007. That would essentially ban 99 percent of all ...
(Date:5/5/2016)... ... , ... This weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes from ... Team Semper Fi Mountain Bike Camp, hosted in conjunction with WTB and ... and Jason Moeschler, who’ll share pro tips with the injured veterans as they rip down ...
(Date:5/5/2016)... ... May 05, 2016 , ... LELO has discovered many people ... fans reach out via email, social media and on the Volonté blog seeking advice ... way I masturbate ‘normal’ or ‘correct’?” , While some methods are more common than ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... in all U.S. states and certain Canadian provinces is now available from the ... Research Institute (WCRI). , The report, Workers’ Compensation Laws as of ...
(Date:5/5/2016)... ... 05, 2016 , ... Long Island’s fastest growing comprehensive eye care provider, ... surgeon, Kathleen Van Valkenburg, MD as part of their ongoing effort to increase ophthalmic ... and managing partner of North Shore Eye Care. , “We are extremely proud ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Research and ... Actinic Keratosis Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Landscape Highlights 2016, provides comprehensive insights into ... Actinic Keratosis market valuations and forecast, Actinic ...
(Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
Breaking Medicine Technology: